CHRNA2

Across TCGA pan-cancer cohorts, CHRNA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHRNA2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CHRNA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHRNA2 expression acts as an unfavorable survival marker.

GBM, LSCC, and LUAD are the cancer types where CHRNA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.314	0.588	.005	18	view →
LSCC	DFS	Quartile	All	0.598	0.911	.003	10	view →
LUAD	OS	Quartile	III,IV	0.322	0.991	.038	6	view →
HNSC	OS	Median	II,III,IV	0.637	0.825	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHRNA2–GBM (OS)

Open the GBM breakdown →